Guardant Health (DE:5GH)

NASDAQ:5GH

5GH

Guardant Health

RESEARCH TOOLSreports

Guardant Health (5GH) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

5GH Analyst Ratings

Strong Buy

21 Buy

0 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Guardant

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

5GH Stock 12 Month Forecast

Average Price Target

€129.07

▲(78.28% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is €129.07 with a high forecast of €162.85 and a low forecast of €110.03. The average price target represents a 78.28% change from the last price of €72.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","163":"€163","66.25":"€66.3","98.5":"€98.5","130.75":"€130.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":162.8462352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€162.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.07243563789473,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€129.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.03124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€110.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,66.25,98.5,130.75,163],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.3,115.26509501538462,119.23019003076922,123.19528504615384,127.16038006153846,131.12547507692307,135.0905700923077,139.0556651076923,143.0207601230769,146.98585513846155,150.95095015384615,154.91604516923076,158.8811401846154,{"y":162.8462352,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.3,112.6671104336842,114.03422086736842,115.40133130105262,116.76844173473684,118.13555216842104,119.50266260210526,120.86977303578946,122.23688346947368,123.60399390315789,124.9711043368421,126.3382147705263,127.70532520421051,{"y":129.07243563789473,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.3,111.20240307692308,111.10480615384616,111.00720923076923,110.9096123076923,110.81201538461538,110.71441846153846,110.61682153846154,110.51922461538462,110.4216276923077,110.32403076923076,110.22643384615384,110.12883692307692,{"y":110.03124,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€162.85

Average Price Target€129.07

Lowest Price Target€110.03

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eve Burstein

Bernstein

€154.04

Buy

112.77%

Upside

Assigned

06/25/26

Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Guardant Health (NASDAQ: GH) and Biogen (NASDAQ: BIIB)

Luke Sergott

Barclays

€105.63→€132.04

Buy

82.37%

Upside

Assigned

06/24/26

Barclays Sticks to Its Buy Rating for Guardant Health (GH)

Brandon Couillard

Wells Fargo

€110.03

Buy

51.98%

Upside

Reiterated

06/17/26

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), BridgeBio Pharma (NASDAQ: BBIO) and Guardant Health (NASDAQ: GH)

Dan Leonard

RBC Capital

€162.85

Buy

124.93%

Upside

Initiated

06/12/26

Guardant Health initiated with an Outperform at RBC CapitalGuardant Health initiated with an Outperform at RBC Capital

Bradley Bowers

Mizuho Securities

€118.83→€154.04

Buy

112.77%

Upside

Reiterated

06/08/26

Guardant Health price target raised to $175 from $135 at MizuhoGuardant Health price target raised to $175 from $135 at Mizuho

Evie Koslosky

Goldman Sachs

€145.24

Buy

100.61%

Upside

Initiated

06/05/26

Guardant Health initiated with a Buy at Goldman SachsGuardant Health initiated with a Buy at Goldman Sachs

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

06/02/26

Leerink Partners Reaffirms Their Buy Rating on Guardant Health (GH)

Vijay Kumar

Evercore ISI

€83.62→€140.84

Buy

94.53%

Upside

Upgraded

06/02/26

Guardant Health upgraded to Outperform from In Line at Evercore ISIGuardant Health upgraded to Outperform from In Line at Evercore ISI

Subbu Nambi

Guggenheim

€118.83

Buy

64.13%

Upside

Reiterated

05/28/26

Guggenheim Sticks to Their Buy Rating for Guardant Health (GH)

David Westenberg

Piper Sandler

€118.83

Buy

64.13%

Upside

Reiterated

05/28/26

Guardant Health (GH) Gets a Buy from Piper Sandler

Daniel Arias

Stifel Nicolaus

€114.43

Buy

58.06%

Upside

Reiterated

05/28/26

Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)

Kyle Mikson CFA

Canaccord Genuity

€118.83

Buy

64.13%

Upside

Reiterated

05/28/26

Canaccord Genuity Reaffirms Their Buy Rating on Guardant Health (GH)

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

05/27/26

Stifel Reiterates Buy on Guardant Health as ACS Guideline Inclusion of Shield Test Expands Market Opportunity

Kallum Titchmarsh

Morgan Stanley

€85.13→€114.43

Buy

58.06%

Upside

Reiterated

05/27/26

Guardant Health: ACS Shield Endorsement and Camizestrant FDA Tailwind Prompt Price Target Increase to $130 and Reinforce Buy Rating

Mark Massaro

BTIG

€136.44→€140.84

Buy

94.53%

Upside

Reiterated

05/27/26

Guardant Health price target raised to $155 from $145 at BTIGGuardant Health price target raised to $155 from $145 at BTIG

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eve Burstein

Bernstein

€154.04

Buy

112.77%

Upside

Assigned

06/25/26

Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Guardant Health (NASDAQ: GH) and Biogen (NASDAQ: BIIB)

Luke Sergott

Barclays

€105.63→€132.04

Buy

82.37%

Upside

Assigned

06/24/26

Barclays Sticks to Its Buy Rating for Guardant Health (GH)

Brandon Couillard

Wells Fargo

€110.03

Buy

51.98%

Upside

Reiterated

06/17/26

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), BridgeBio Pharma (NASDAQ: BBIO) and Guardant Health (NASDAQ: GH)

Dan Leonard

RBC Capital

€162.85

Buy

124.93%

Upside

Initiated

06/12/26

Guardant Health initiated with an Outperform at RBC CapitalGuardant Health initiated with an Outperform at RBC Capital

Bradley Bowers

Mizuho Securities

€118.83→€154.04

Buy

112.77%

Upside

Reiterated

06/08/26

Guardant Health price target raised to $175 from $135 at MizuhoGuardant Health price target raised to $175 from $135 at Mizuho

Evie Koslosky

Goldman Sachs

€145.24

Buy

100.61%

Upside

Initiated

06/05/26

Guardant Health initiated with a Buy at Goldman SachsGuardant Health initiated with a Buy at Goldman Sachs

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

06/02/26

Leerink Partners Reaffirms Their Buy Rating on Guardant Health (GH)

Vijay Kumar

Evercore ISI

€83.62→€140.84

Buy

94.53%

Upside

Upgraded

06/02/26

Guardant Health upgraded to Outperform from In Line at Evercore ISIGuardant Health upgraded to Outperform from In Line at Evercore ISI

Subbu Nambi

Guggenheim

€118.83

Buy

64.13%

Upside

Reiterated

05/28/26

Guggenheim Sticks to Their Buy Rating for Guardant Health (GH)

David Westenberg

Piper Sandler

€118.83

Buy

64.13%

Upside

Reiterated

05/28/26

Guardant Health (GH) Gets a Buy from Piper Sandler

Daniel Arias

Stifel Nicolaus

€114.43

Buy

58.06%

Upside

Reiterated

05/28/26

Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)

Kyle Mikson CFA

Canaccord Genuity

€118.83

Buy

64.13%

Upside

Reiterated

05/28/26

Canaccord Genuity Reaffirms Their Buy Rating on Guardant Health (GH)

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

05/27/26

Stifel Reiterates Buy on Guardant Health as ACS Guideline Inclusion of Shield Test Expands Market Opportunity

Kallum Titchmarsh

Morgan Stanley

€85.13→€114.43

Buy

58.06%

Upside

Reiterated

05/27/26

Guardant Health: ACS Shield Endorsement and Camizestrant FDA Tailwind Prompt Price Target Increase to $130 and Reinforce Buy Rating

Mark Massaro

BTIG

€136.44→€140.84

Buy

94.53%

Upside

Reiterated

05/27/26

Guardant Health price target raised to $155 from $145 at BTIGGuardant Health price target raised to $155 from $145 at BTIG

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months

William BonelloCraig-Hallum

Success Rate

10/14 ratings generated profit

Average Return

+40.11%

Copying William Bonello's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +40.11% per trade.

1 Year

William BonelloCraig-Hallum

Success Rate

14/14 ratings generated profit

Average Return

+131.81%

Copying William Bonello's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +131.81% per trade.

2 Years

William BonelloCraig-Hallum

Success Rate

14/14 ratings generated profit

Average Return

+245.11%

Copying William Bonello's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +245.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5GH Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 5GH has received 48 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 5GH average Analyst price target in the past 3 months is 129.07.

Each month's total comprises the sum of three months' worth of ratings.

5GH Financial Forecast

5GH Earnings Forecast

Next quarter’s earnings estimate for 5GH is -€0.66 with a range of -€0.73 to -€0.53. The previous quarter’s EPS was -€0.75. 5GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 5GH has Performed in-line its overall industry.

5GH Sales Forecast

Next quarter’s sales forecast for 5GH is €276.19M with a range of €264.78M to €283.53M. The previous quarter’s sales results were €265.54M. 5GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 5GH has Performed in-line its overall industry.

5GH Stock Forecast FAQ

What is DE:5GH’s average 12-month price target, according to analysts?

Based on analyst ratings, Guardant Health’s 12-month average price target is 129.07.

What is DE:5GH’s upside potential, based on the analysts’ average price target?

Guardant Health has 78.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Guardant Health a Buy, Sell or Hold?

Guardant Health has a consensus rating of Strong Buy, which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.

What is Guardant Health’s share price target?

The average share price target for Guardant Health is 129.07. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €162.85 ,and the lowest forecast is €110.03. The average share price target represents 78.28% Increase from the current price of €72.4.

What do analysts say about Guardant Health?

Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Guardant Health?

To buy shares of DE:5GH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Guardant Health (5GH) Stock Forecast & Price Target

5GH Analyst Ratings

5GH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Guardant Health

5GH Analyst Recommendation Trends

5GH Financial Forecast

5GH Earnings Forecast

5GH Sales Forecast

5GH Stock Forecast FAQ

Detailed List of Analyst Forecasts